ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS)
Author
Buti, M.
Flisiak, R.
Rasenack, J.
Davis, G.
Alberti, A.
Goeser, T.
Stanciu, C.
Chuang, W. -L.
Kao, J. -H.
Streinu-Cercel, A.
Hofstetter, G.
Wang, J.
Avila, C.
Orsenigo, R.
Tabak, F.
Metadata
Show full item recordCollections
- Bildiri [64839]